

# Sharon J Hutchinson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5694008/publications.pdf>

Version: 2024-02-01

186  
papers

9,436  
citations

53660

45  
h-index

43802

91  
g-index

191  
all docs

191  
docs citations

191  
times ranked

8244  
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of drug-related deaths soon after release from prison. <i>Addiction</i> , 2010, 105, 1545-1554.	1.7	518
2	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , 2013, 58, 1598-1609.	3.6	431
3	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 135-184.	3.7	370
4	Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. <i>International Journal of Epidemiology</i> , 2014, 43, 235-248.	0.9	298
5	Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, S80-S89.	2.9	280
6	Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy. <i>Clinical Infectious Diseases</i> , 2013, 57, S39-S45.	2.9	275
7	The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. <i>Addiction</i> , 2011, 106, 1978-1988.	1.7	271
8	Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. <i>BMJ</i> , The, 2020, 371, m3582.	3.0	261
9	The EASL "Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	6.3	257
10	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 82-93.	5.5	251
11	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. <i>Addiction</i> , 2018, 113, 545-563.	1.7	242
12	Interventions to prevent HIV and Hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness. <i>International Journal of Drug Policy</i> , 2014, 25, 34-52.	1.6	238
13	Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. <i>Addiction</i> , 2010, 105, 844-859.	1.7	209
14	Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. <i>Addiction</i> , 2003, 98, 185-190.	1.7	205
15	Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. <i>Journal of Hepatology</i> , 2011, 54, 1137-1144.	1.8	199
16	Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. <i>Hepatology</i> , 2012, 55, 49-57.	3.6	194
17	Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. <i>PLoS ONE</i> , 2014, 9, e103345.	1.1	184
18	Influence of Alcohol on the Progression of Hepatitis C Virus Infection: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1150-1159.	2.4	182

#	ARTICLE	IF	CITATIONS
19	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. The Cochrane Library, 2017, 2017, CD012021.	1.5	158
20	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 2020, 73, 1368-1378.	1.8	158
21	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. Journal of Hepatology, 2016, 65, 17-25.	1.8	157
22	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1397-1409.	4.6	147
23	Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology, 2005, 42, 711-723.	3.6	114
24	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Journal of Hepatology, 2018, 68, 402-411.	1.8	105
25	Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology, 2015, 62, 355-364.	3.6	102
26	<sc>HCV</sc> treatment rates and sustained viral response among people who inject drugs in seven <sc>UK</sc> sites: real world results and modelling of treatment impact. Journal of Viral Hepatitis, 2015, 22, 399-408.	1.0	86
27	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. Journal of Hepatology, 2018, 68, 646-654.	1.8	82
28	Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction, 2017, 112, 1302-1314.	1.7	80
29	Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions. PLoS ONE, 2014, 9, e104515.	1.1	79
30	Hepatitis C virus treatment as prevention in people who inject drugs. Current Opinion in Infectious Diseases, 2015, 28, 576-582.	1.3	78
31	Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 2013, 3, e003153.	0.8	74
32	Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017. JHEP Reports, 2019, 1, 81-89.	2.6	74
33	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. PLoS Medicine, 2020, 17, e1003374.	3.9	61
34	Detection of hepatitis C virus RNA in dried blood spots. Journal of Clinical Virology, 2012, 54, 106-109.	1.6	60
35	Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. Journal of Epidemiology and Community Health, 2014, 68, 1182-1188.	2.0	60
36	Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis <sc>C</sc> virus (<sc>HCV</sc>) infection using cross-sectional survey data. Journal of Viral Hepatitis, 2014, 21, 25-32.	1.0	58

#	ARTICLE	IF	CITATIONS
37	Is increased hepatitis C virus caseâ€finding combined with current or 8â€week to 12â€week directâ€acting antiviral therapy costâ€effective in UK prisons? A prevention benefit analysis. <i>Hepatology</i> , 2016, 63, 1796-1808.	3.6	58
38	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. <i>Journal of Hepatology</i> , 2018, 68, 393-401.	1.8	58
39	Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. <i>Hepatology</i> , 2011, 54, 1547-1558.	3.6	54
40	A recordâ€linkage study of drugâ€related death and suicide after hospital discharge among drugâ€treatment clients in <sc>S</sc>cotland, 1996â€2006. <i>Addiction</i> , 2013, 108, 377-384.	1.7	54
41	Mortality of those who attended drug services in Scotland 1996â€2006: Record-linkage study. <i>International Journal of Drug Policy</i> , 2012, 23, 24-32.	1.6	53
42	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , 2020, 159, 1276-1289.e7.	0.6	53
43	One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. <i>Addiction</i> , 2000, 95, 1055-1068.	1.7	51
44	Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: Implications for treatment cost-effectiveness. <i>Hepatology</i> , 2013, 57, 451-460.	3.6	51
45	A global investment framework for the elimination of hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 535-549.	1.8	51
46	Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. <i>Lancet HIV</i> , 2019, 6, e315-e324.	2.1	50
47	Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-94: implications for control and prevention of blood-borne viruses. <i>Addiction</i> , 2000, 95, 931-940.	1.7	49
48	Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. <i>Gut</i> , 2015, 64, 1800-1809.	6.1	49
49	High response and reâ€infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. <i>Journal of Viral Hepatitis</i> , 2019, 26, 519-528.	1.0	48
50	A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. <i>Statistical Methods in Medical Research</i> , 2009, 18, 271-283.	0.7	45
51	A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 1009-1016.	1.0	44
52	Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. <i>Journal of Hepatology</i> , 2017, 66, 19-27.	1.8	44
53	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. <i>Liver International</i> , 2019, 39, 1818-1836.	1.9	44
54	Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. <i>International Journal of Drug Policy</i> , 2014, 25, 179-182.	1.6	43

#	ARTICLE	IF	CITATIONS
55	Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. <i>Drug and Alcohol Dependence</i> , 2016, 165, 53-60.	1.6	43
56	Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. <i>Journal of Hepatology</i> , 2013, 58, 460-466.	1.8	42
57	Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: Implications for prevention. <i>International Journal of Drug Policy</i> , 2006, 17, 211-221.	1.6	41
58	Drug-related deaths by region, sex, and age group per 100 injecting drug users in Scotland, 2000-2011. <i>Lancet, The</i> , 2003, 362, 941-944.	6.3	40
59	Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. <i>International Journal of Drug Policy</i> , 2012, 23, 346-352.	1.6	39
60	Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM. <i>Aids</i> , 2021, 35, 665-673.	1.0	38
61	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
62	Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment. <i>Journal of Hepatology</i> , 2015, 62, 269-277.	1.8	36
63	Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. <i>Liver International</i> , 2019, 39, 2244-2260.	1.9	36
64	Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 77, 102663.	1.6	36
65	Association of self-reported alcohol use and hospitalization for an alcohol-related cause in Scotland: a record-linkage study of 23 183 individuals. <i>Addiction</i> , 2009, 104, 593-602.	1.7	34
66	Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. <i>Journal of Clinical Virology</i> , 2014, 61, 359-364.	1.6	33
67	Drugs-Related Death Soon after Hospital-Discharge among Drug Treatment Clients in Scotland: Record Linkage, Validation, and Investigation of Risk-Factors. <i>PLoS ONE</i> , 2015, 10, e0141073.	1.1	33
68	Modelling the prevalence of HCV amongst people who inject drugs: An investigation into the risks associated with injecting paraphernalia sharing. <i>Drug and Alcohol Dependence</i> , 2013, 133, 172-179.	1.6	32
69	Cost-Effectiveness of HBV and HCV Screening Strategies - A Systematic Review of Existing Modelling Techniques. <i>PLoS ONE</i> , 2015, 10, e0145022.	1.1	32
70	Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , 2015, 30, 115-129.	2.5	32
71	Prior Information in Behavioral Capture-Recapture Methods: Demographic Influences on Drug Injectors' Propensity to Be Listed in Data Sources and Their Drug-related Mortality. <i>American Journal of Epidemiology</i> , 2005, 162, 694-703.	1.6	30
72	Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings - what is required to achieve the WHO's HCV elimination targets?. <i>Addiction</i> , 2018, 113, 1727-1738.	1.7	30

#	ARTICLE	IF	CITATIONS
73	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	0.8	30
74	Engagement in a National Naloxone Programme among people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2016, 162, 236-240.	1.6	29
75	The contribution of health risk behaviors to excess mortality in American adults with chronic hepatitis C: A population cohort study. <i>Hepatology</i> , 2018, 67, 97-107.	3.6	29
76	Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. <i>Addiction</i> , 2019, 114, 560-570.	1.7	29
77	Estimating current injectors in Scotland and their drug-related death rate by sex, region and age-group via Bayesian capture-recapture methods. <i>Statistical Methods in Medical Research</i> , 2009, 18, 341-359.	0.7	28
78	Global hepatitis C elimination: an investment framework. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 927-939.	3.7	28
79	Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct acting anti-viral therapy in community drug services: real-world data. <i>Addiction</i> , 2021, 116, 2893-2907.	1.7	28
80	Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 646-655.	0.8	27
81	Estimating Prevalence of Injecting Drug Users and Associated Heroin-Related Death Rates in England by Using Regional Data and Incorporating Prior Information. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2014, 177, 209-236.	0.6	27
82	Incomplete contingency tables with censored cells with application to estimating the number of people who inject drugs in Scotland. <i>Statistics in Medicine</i> , 2014, 33, 1564-1579.	0.8	27
83	Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. <i>International Journal of Epidemiology</i> , 2017, 46, 1391-1391h.	0.9	27
84	Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 270-280.	1.0	27
85	The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic review. <i>BMC Public Health</i> , 2010, 10, 721.	1.2	26
86	Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. <i>International Journal of Drug Policy</i> , 2015, 26, 1041-1049.	1.6	25
87	Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2017, 174, 91-97.	1.6	25
88	Sudden rise in uptake of hepatitis B vaccination among injecting drug users associated with a universal vaccine programme in prisons. <i>Vaccine</i> , 2004, 23, 210-214.	1.7	24
89	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	1.9	24
90	Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 948-953.	3.7	24

#	ARTICLE	IF	CITATIONS
91	Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. <i>Journal of Hepatology</i> , 2022, 76, 549-557.	1.8	24
92	Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. <i>International Journal of Drug Policy</i> , 2013, 24, 85-100.	1.6	23
93	Injecting drug users in Scotland, 2006: Listing, number, demography, and opiate-related death-rates. <i>Addiction Research and Theory</i> , 2013, 21, 235-246.	1.2	23
94	Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs. <i>Addiction</i> , 2018, 113, 80-90.	1.7	23
95	Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 566-572.	5.2	23
96	Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. <i>Addiction</i> , 2015, 110, 1287-1300.	1.7	22
97	Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan. <i>Journal of Viral Hepatitis</i> , 2014, 21, 366-376.	1.0	21
98	Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. <i>Public Health Research</i> , 2017, 5, 1-118.	0.5	20
99	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 473-481.	1.0	19
100	Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. <i>Journal of Hepatology</i> , 2014, 60, 1118-1126.	1.8	18
101	Comparative effectiveness of antiviral treatment for hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 882-894.	0.8	17
102	Mortality and cause of death in a cohort of people who had ever injected drugs in Glasgow: 1982-2012. <i>Drug and Alcohol Dependence</i> , 2015, 147, 215-221.	1.6	17
103	Prison-based prescriptions aid Scotland's National Naloxone Programme. <i>Lancet, The</i> , 2017, 389, 1005-1006.	6.3	17
104	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. <i>Gut</i> , 2020, 69, 2223-2231.	6.1	17
105	Estimating the number of injecting drug users in Scotland's HCV-diagnosed population using capture-recapture methods. <i>Epidemiology and Infection</i> , 2014, 142, 200-207.	1.0	16
106	Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: A systematic review. <i>International Journal of Drug Policy</i> , 2011, 22, 102-108.	1.6	15
107	A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. <i>Journal of Clinical Virology</i> , 2013, 57, 29-35.	1.6	15
108	Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort. <i>Journal of Hepatology</i> , 2017, 66, S22-S23.	1.8	15

#	ARTICLE	IF	CITATIONS
109	Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. <i>Addiction</i> , 2018, 113, 2118-2131.	1.7	15
110	Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: impact of study recruitment setting. <i>Epidemiology and Infection</i> , 2013, 141, 563-572.	1.0	14
111	Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection. <i>Drug and Alcohol Dependence</i> , 2015, 154, 125-131.	1.6	14
112	Global policy and access to new hepatitis C therapies for people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1064-1071.	1.6	14
113	Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the pre-direct-acting antiviral era. <i>Journal of Viral Hepatitis</i> , 2017, 24, 295-303.	1.0	14
114	Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. <i>Journal of Viral Hepatitis</i> , 2018, 25, 930-938.	1.0	14
115	Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 49-57.	0.8	13
116	Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland-Using spontaneous resolvers as the benchmark comparator. <i>Hepatology</i> , 2016, 63, 1506-1516.	3.6	13
117	Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era. <i>International Journal of Drug Policy</i> , 2018, 52, 115-122.	1.6	13
118	Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an HIV outbreak: A qualitative study. <i>International Journal of Drug Policy</i> , 2021, 88, 103033.	1.6	13
119	Examining the impact of the first wave of COVID-19 and associated control measures on interventions to prevent blood-borne viruses among people who inject drugs in Scotland: an interrupted time series study. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109263.	1.6	13
120	Trends in the incidence of HIV in Scotland, 1988-2009. <i>Sexually Transmitted Infections</i> , 2012, 88, 194-199.	0.8	12
121	A time since onset of injection model for hepatitis C spread amongst injecting drug users. <i>Journal of Mathematical Biology</i> , 2013, 66, 935-978.	0.8	12
122	Limited impact of awareness-raising campaigns on hepatitis C testing practices among general practitioners. <i>Journal of Viral Hepatitis</i> , 2017, 24, 944-954.	1.0	12
123	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. <i>PLoS ONE</i> , 2020, 15, e0235715.	1.1	12
124	Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity. <i>Hepatology</i> , 2022, 75, 369-378.	3.6	12
125	Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, Scotland. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 568-579.	1.9	12
126	The prevalence of hepatitis C virus among people of South Asian origin in Glasgow - Results from a community based survey and laboratory surveillance. <i>Travel Medicine and Infectious Disease</i> , 2013, 11, 301-309.	1.5	11



#	ARTICLE	IF	CITATIONS
127	Emergence of Novel Psychoactive Substance injecting associated with rapid rise in the population prevalence of hepatitis C virus. <i>International Journal of Drug Policy</i> , 2019, 66, 30-37.	1.6	11
128	Use of laboratory-based surveillance data to estimate the number of people chronically infected with hepatitis B living in Scotland. <i>Epidemiology and Infection</i> , 2014, 142, 2121-2130.	1.0	10
129	What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?. <i>Journal of Hepatology</i> , 2015, 62, 262-268.	1.8	10
130	High willingness to use drug consumption rooms among people who inject drugs in Scotland: findings from a national bio-behavioural survey among people who inject drugs. <i>International Journal of Drug Policy</i> , 2021, 90, 102731.	1.6	10
131	The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1452-1463.	1.0	10
132	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , 2021, 3, 100384.	2.6	10
133	The successful implementation of Scotland's Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective. <i>BMC Infectious Diseases</i> , 2014, 14, S7.	1.3	9
134	Missing targets on drugs-related deaths, and a Scottish paradox. <i>International Journal of Drug Policy</i> , 2010, 21, 155-159.	1.6	8
135	A record linkage study of hospital episodes for drug treatment clients in Scotland, 1996-2006. <i>Addiction Research and Theory</i> , 2013, 21, 52-61.	1.2	8
136	Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2016, 23, 596-605.	1.0	8
137	Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis. <i>Liver International</i> , 2018, 38, 1402-1410.	1.9	8
138	The Scottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. <i>PLoS ONE</i> , 2016, 11, e0162980.	1.1	8
139	Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: A population-based cohort study. <i>Liver International</i> , 2022, 42, 561-574.	1.9	8
140	Estimating the prevalence, incidence and cessation of injecting drug use in Glasgow 1960-2000: Combining expert opinion with capture-recapture prevalence data. <i>International Journal of Drug Policy</i> , 2006, 17, 29-34.	1.6	7
141	Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype. <i>Journal of Viral Hepatitis</i> , 2020, 27, 996-1002.	1.0	7
142	The association between alcohol use and hepatitis C status among injecting drug users in Glasgow. <i>Drug and Alcohol Dependence</i> , 2012, 123, 180-189.	1.6	6
143	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. <i>Journal of Medical Virology</i> , 2018, 90, 120-130.	2.5	6
144	Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis. <i>Journal of Hepatology</i> , 2018, 68, S67.	1.8	6

#	ARTICLE	IF	CITATIONS
145	Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005â€”2016: a national database linkage study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 425-434.	1.9	6
146	P734 A SYSTEMATIC REVIEW OF INTERVENTIONS TO REDUCE ALCOHOL CONSUMPTION AMONG INDIVIDUALS WITH CHRONIC HCV INFECTION. <i>Journal of Hepatology</i> , 2014, 60, S314-S315.	1.8	5
147	Modeling the Initiation of Others Into Injection Drug Use, Using Data From 2,500 Injectors Surveyed in Scotland During 2008â€”2009. <i>American Journal of Epidemiology</i> , 2015, 181, 771-780.	1.6	5
148	Evaluation of the scale-up of HIV testing among people who inject drugs in Scotland in the context of an ongoing HIV outbreak. <i>International Journal of Drug Policy</i> , 2021, 96, 103304.	1.6	4
149	The uptake of foil from needle and syringe provision services and its role in smoking or snorting heroin among people who inject drugs in Scotland. <i>International Journal of Drug Policy</i> , 2021, 98, 103369.	1.6	4
150	Targets for Hepatitis C virus test uptake and case-finding among injecting drug users: In prisons and general practice. <i>Addiction Research and Theory</i> , 2010, 18, 421-432.	1.2	3
151	P1271 : How should scale up of HCV antiviral treatment be prioritized? A cost-effectiveness analysis including individual and population prevention benefits. <i>Journal of Hepatology</i> , 2015, 62, S835.	1.8	3
152	The seroprevalence of hepatitis C virus infection among children and their mothers attending for dental care in Glasgow, Scotland, United Kingdom. <i>Journal of Infection and Public Health</i> , 2017, 10, 470-478.	1.9	3
153	Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality - results from two surveys (2016). <i>HIV Medicine</i> , 2018, 19, 11-15.	1.0	3
154	Strategies to reduce <scp>HCV</scp> disease burden and <scp>HCV</scp> transmission need different models, as what works for endâ€”stage liver disease may not work for <scp>HCV</scp> prevalence: a comment on the results presented in <scp>JVH</scp> Special Issue. <i>Journal of Viral Hepatitis</i> , 2014, 21, e167-8.	1.0	2
155	The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 398-404.	0.8	2
156	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. <i>Addiction</i> , 2017, 112, 1126-1127.	1.7	2
157	Spore forming bacteria infections and people who inject drugs: Implications for harm reduction. <i>International Journal of Drug Policy</i> , 2018, 53, 45-54.	1.6	2
158	Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awarenessâ€”raising campaign. <i>Journal of Viral Hepatitis</i> , 2019, 26, 93-100.	1.0	2
159	Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-stratification in Patients with Hepatitis C Cirrhosis.. <i>Clinical and Translational Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.3	2
160	965 TRENDS IN MORTALITY AFTER DIAGNOSIS OF HEPATITIS C INFECTION â€” AN INTERNATIONAL COMPARISON. <i>Journal of Hepatology</i> , 2013, 58, S397-S398.	1.8	1
161	O124 : Is increased HCV case-finding combined with 8 or 12 week interferon-free direct-acting antiviral treatment cost-effective in UK prisons? a cost utility analysis including treatment as prevention benefits. <i>Journal of Hepatology</i> , 2015, 62, S255-S256.	1.8	1
162	The reported â€”clear cut time association between interferon-free treatment and HCCâ€” is anything but clear cut. <i>Journal of Hepatology</i> , 2020, 72, 1034-1035.	1.8	1

#	ARTICLE	IF	CITATIONS
163	Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1246-1255.	1.0	1
164	Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention. <i>Statistical Communications in Infectious Diseases</i> , 2021, 13, .	0.2	1
165	Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making. , 2022, 1, 129-136.		1
166	979 COST-EFFECTIVENESS OF INCREASING HCV CASE-FINDING FOR PEOPLE WHO INJECT DRUGS VIA DRIED BLOOD SPOT TESTING IN ADDICTION SERVICES AND PRISONS. <i>Journal of Hepatology</i> , 2013, 58, S403-S404.	1.8	0
167	867 ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS. <i>Journal of Hepatology</i> , 2013, 58, S356.	1.8	0
168	P1292 EVIDENCE OF CONTINUED INJECTING DRUG USE AFTER ATTAINING SUSTAINED TREATMENT-INDUCED CLEARANCE OF THE HEPATITIS C VIRUS: IMPLICATIONS FOR RE-INFECTION. <i>Journal of Hepatology</i> , 2014, 60, S520-S521.	1.8	0
169	O91 EVIDENCE OF REINFECTION WITH HEPATITIS C FOLLOWING SUCCESSFUL TREATMENT WITH ANTIVIRAL THERAPY AMONG PEOPLE WHO INJECT DRUGS IN SCOTLAND. <i>Journal of Hepatology</i> , 2014, 60, S37.	1.8	0
170	P1289 CAN COMBINATION HCV PREVENTION INTERVENTIONS IN THE DAA ERA RESULT IN DRAMATIC REDUCTIONS IN HCV PREVALENCE? A MODELING ANALYSIS IN SETTINGS WITH EXISTING HARM REDUCTION. <i>Journal of Hepatology</i> , 2014, 60, S519.	1.8	0
171	PTH-104...Hospital Admissions and Associated Costs of Alcoholic Liver Disease in Scotland Between 1991 and 2011. <i>Gut</i> , 2016, 65, A270.1-A270.	6.1	0
172	Does Alcohol Dependency Explain Differences in Rates of Decompensated Cirrhosis among People with a Hepatitis C Notification? An International Comparison. <i>Journal of Hepatology</i> , 2016, 64, S462-S463.	1.8	0
173	Incarceration of People who inject Drugs – Modelling its Role in HCV Transmission and the Impact of Scaled-Up HCV Treatment in Prisons. <i>Journal of Hepatology</i> , 2016, 64, S811.	1.8	0
174	Comparing Individual and Population Prevention Benefits of Early Direct-Acting Antiviral Treatment for HCV. <i>Journal of Hepatology</i> , 2016, 64, S464.	1.8	0
175	Reply. <i>Hepatology</i> , 2018, 67, 1173-1173.	3.6	0
176	Poor awareness of liver disease shortly before cirrhosis death: findings from a large community cohort in the UK. <i>Journal of Hepatology</i> , 2018, 68, S151-S152.	1.8	0
177	PS-065-The global investment case for hepatitis C elimination. <i>Journal of Hepatology</i> , 2019, 70, e39-e40.	1.8	0
178	Title is missing!. , 2020, 17, e1003374.		0
179	Title is missing!. , 2020, 17, e1003374.		0
180	Title is missing!. , 2020, 17, e1003374.		0

#	ARTICLE	IF	CITATIONS
181	Title is missing!. , 2020, 17, e1003374.		0
182	Title is missing!. , 2020, 17, e1003374.		0
183	Title is missing!. , 2020, 15, e0235715.		0
184	Title is missing!. , 2020, 15, e0235715.		0
185	Title is missing!. , 2020, 15, e0235715.		0
186	Title is missing!. , 2020, 15, e0235715.		0